Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are patients at one of the participating medical centres that have passed a data review by the National Clinical Center for Skin and Immune Diseases.
- People who have received a confirmed diagnosis of primary cutaneous lymphoma (a type of lymphoma that starts in the skin) based on a skin biopsy.
Who may not be able to join:
- People who are unable or unwilling to provide a signed informed consent form.
- People who are unable to complete a questionnaire on their own or with guidance from the research team.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yang Wang, MD, Peking University First Hospital
Phone: (86)-10-83572350
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Type of significant therapies; Duration of significant therapies; Clinical response to significant therapies; Objective response rate(ORR); Time-to-next treatment (TTNT); Time to response (TTR); Time to treatment failure (TTF)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.